Advertisement

Analysis of Conservative Treatment of Upper Tract Urothelial Carcinoma

  • Joel Hillelsohn
  • Ariel Schulman
  • Majid Eshghi
Chapter

Abstract

A survey of literature on UTUC shows a mix set of results on efficacy and outcome of conservative treatment. There are no standardized templates for ureteroscopic or percutaneous resection techniques nor the adjuvant treatment options. The assumptions of what institutes a diagnosis or success after treatment also remain unclear. The conservative management of UTUC is a work in progress requiring a multicenter prospective evaluation to provide more clear parameters to follow.

Keywords

Analysis of TCC data Long-term results Topical chemotherapy Percutaneous treatment of TCC BCG Mitomycin C Ureteroscopic treatment Percutaneous treatment Conservative treatment Recurrence of UTUC 

References

  1. 1.
    Schmeller NT, Hofstetter AG. Laser treatment of ureteral tumors. J Urol. 1989;141:840.CrossRefPubMedGoogle Scholar
  2. 2.
    Gaboardi F, Bozzola A, Dotti E, et al. Conservative treatment of upper urinary tract tumors with Nd:YAG laser. J Endourol. 1994;8:37.CrossRefPubMedGoogle Scholar
  3. 3.
    Martinez-Piñeiro JA, Garcia Matres MJ, Martinez-Piñeiro L. Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol. 1996;156:377.CrossRefPubMedGoogle Scholar
  4. 4.
    Roupret M, Hupertan V, Traxer O, et al. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology. 2006;67:1181.CrossRefPubMedGoogle Scholar
  5. 5.
    Lucas SM, Svatek RS, Olgin G, et al. Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int. 2008;102:172.CrossRefPubMedGoogle Scholar
  6. 6.
    Cutress ML, Stewart GD, Zakikhani P, et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012;110:614.CrossRefPubMedGoogle Scholar
  7. 7.
    Grasso M, Fishman AI, Cohen J, et al. Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int. 2012;110:1618.CrossRefPubMedGoogle Scholar
  8. 8.
    Gadzinski AJ, Roberts WW, Faerber GJ, et al. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J Endourol. 2012;26:566.CrossRefPubMedGoogle Scholar
  9. 9.
    Raymundo EM, Lipkin ME, Bañez LB, et al. Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. J Endourol. 2011;25:377.CrossRefPubMedGoogle Scholar
  10. 10.
    Pak RW, Moskowitz EJ, Bagley DH. What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival. J Endourol. 2009;23:341.CrossRefPubMedGoogle Scholar
  11. 11.
    Engelmyer EI, Belis JA. Long-term ureteroscopic management of low-grade transitional cell carcinoma of the upper urinary tract. Tech Urol. 1996;2:113.PubMedGoogle Scholar
  12. 12.
    Daneshmand S, Quek ML, Huffman JL. Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience. Cancer. 2003;98:55.CrossRefPubMedGoogle Scholar
  13. 13.
    Johnson GB, Fraiman M, Grasso M. Broadening experience with the retrograde endoscopic management of upper urinary tract urothelial malignancies. BJU Int. 2005;95(Suppl. 2):110.CrossRefPubMedGoogle Scholar
  14. 14.
    Krambeck AE, Thompson RH, Lohse CM, et al. Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. J Urol. 2007;177:1721.CrossRefPubMedGoogle Scholar
  15. 15.
    Cornu JN, Rouprêt M, Carpentier X, et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol. 2010;28:151.CrossRefPubMedGoogle Scholar
  16. 16.
    Gadzinski AJ, Roberts WW, Faerber GJ, et al. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol. 2010;183:2148.CrossRefPubMedGoogle Scholar
  17. 17.
    Cutress ML, Stewart GD, Tudor EC, et al. Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience. J Urol. 2013;189:2054.CrossRefPubMedGoogle Scholar
  18. 18.
    Thompson RH, Krambeck AE, Lohse CM, et al. Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology. 2008;71:713.CrossRefPubMedGoogle Scholar
  19. 19.
    Deligne E, Colombel M, Badet L, et al. Conservative management of upper urinary tract tumors. Eur Urol. 2002;42:43.CrossRefPubMedGoogle Scholar
  20. 20.
    Lee BR, Jabbour ME, Marshall FF, et al. 13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: equivalent outcomes. J Endourol. 1999;13:289.CrossRefPubMedGoogle Scholar
  21. 21.
    Fuglsig S, Krarup T. Percutaneous nephroscopic resection of renal pelvic tumors. Scand J Urol Nephrol Suppl. 1995;172:15.PubMedGoogle Scholar
  22. 22.
    Jabbour ME, Smith AD. Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am. 2000;27:739.CrossRefPubMedGoogle Scholar
  23. 23.
    Irwin BH, Berger AK, Brandina R, et al. Complex percutaneous resections for upper-tract urothelial carcinoma. J Endourol. 2010;24:367.CrossRefPubMedGoogle Scholar
  24. 24.
    Tasca A, Zattoni F. The case for a percutaneous approach to transitional cell carcinoma of the renal pelvis. J Urol. 1990;143:902.CrossRefPubMedGoogle Scholar
  25. 25.
    Plancke HR, Strijbos WE, Delaere KP. Percutaneous endoscopic treatment of urothelial tumours of the renal pelvis. Br J Urol. 1995;75:736.CrossRefPubMedGoogle Scholar
  26. 26.
    Patel A, Soonawalla P, Shepherd SF, et al. Long-term outcome after percutaneous treatment of transitional cell carcinoma of the renal pelvis. J Urol. 1996;155:868.CrossRefPubMedGoogle Scholar
  27. 27.
    Martínez-Piñeiro JA, García Matres MJ, Martínez-Piñeiro L. Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol. 1996;156:377.CrossRefPubMedGoogle Scholar
  28. 28.
    Clark PE, Streem SB, Geisinger MA. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol. 1999;161:772.CrossRefPubMedGoogle Scholar
  29. 29.
    Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol. 2003;169:925.CrossRefPubMedGoogle Scholar
  30. 30.
    Suh RS, Faerber GJ, Wolf JS. Predictive factors for applicability and success with endoscopic treatment of upper tract urothelial carcinoma. J Urol. 2003;170:2209.CrossRefPubMedGoogle Scholar
  31. 31.
    Palou J, Piovesan LF, Huguet J, et al. Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol. 2004;172:66.CrossRefPubMedGoogle Scholar
  32. 32.
    Rouprêt M, Traxer O, Tligui M, et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol. 2007;51:709.CrossRefPubMedGoogle Scholar
  33. 33.
    Motamedinia P, Keheila M, Leavitt DA, et al. The expanded use of percutaneous resection for upper tract urothelial carcinoma: a 30-year comprehensive experience. J Endourol. 2015;30:262–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Herr HW. Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin. J Urol. 1985;134:531.CrossRefPubMedGoogle Scholar
  35. 35.
    Nonomura N, Ono Y, Nozawa M, et al. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol. 2000;38:701.CrossRefPubMedGoogle Scholar
  36. 36.
    Okubo K, Ichioka K, Terada N, et al. Intrarenal bacillus Calmette-Guérin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure. BJU Int. 2001;88:343.CrossRefPubMedGoogle Scholar
  37. 37.
    Miyake H, Eto H, Hara S, et al. Clinical outcome of bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract. Int J Urol. 2002;9:677.CrossRefPubMedGoogle Scholar
  38. 38.
    Hayashida Y, Nomata K, Noguchi M, et al. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract. Urology. 2004;63:1084.CrossRefPubMedGoogle Scholar
  39. 39.
    Kojima Y, Tozawa K, Kawai N, et al. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy. Int J Urol. 2006;13:340.CrossRefPubMedGoogle Scholar
  40. 40.
    Giannarini G, Kessler TM, Birkhauser FD, et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol. 2011;60:955.CrossRefPubMedGoogle Scholar
  41. 41.
    Sharpe JR, Duffy G, Chin JL. Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ. J Urol. 1993;149:457.CrossRefPubMedGoogle Scholar
  42. 42.
    Yokogi H, Wada Y, Mizutani M, et al. Bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract. Br J Urol. 1996;77:676.CrossRefPubMedGoogle Scholar
  43. 43.
    Nishino Y, Yamamoto N, Komeda H, et al. Bacillus Calmette-Guérin instillation treatment for carcinoma in situ of the upper urinary tract. BJU Int. 2000;85:799.CrossRefPubMedGoogle Scholar
  44. 44.
    Irie A, Iwamura M, Kadowaki K, et al. Intravesical instillation of bacille Calmette-Guérin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology. 2002;59:53.CrossRefPubMedGoogle Scholar
  45. 45.
    Studer UE, Casanova G, Kraft R, et al. Percutaneous BCG perfusion of the upper urinary tract for carcinoma in situ. Prog Clin Biol Res. 1989;310:207.PubMedGoogle Scholar
  46. 46.
    Schoenberg MP, Van Arsdalen KN, Wein AJ. The management of transitional cell carcinoma in solitary renal units. J Urol. 1991;146:700.CrossRefPubMedGoogle Scholar
  47. 47.
    Jarrett TW, Sweetser PM, Weiss GH, et al. Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J Urol. 1995;154:1629.CrossRefPubMedGoogle Scholar
  48. 48.
    Patel A, Fuchs GJ. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J Urol. 1998;159:71.CrossRefPubMedGoogle Scholar
  49. 49.
    Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy? Urology. 2009;73:27.CrossRefPubMedGoogle Scholar
  50. 50.
    Elliott DS, Blute ML, Patterson DE, et al. Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology. 1996;47:819.CrossRefPubMedGoogle Scholar
  51. 51.
    Keeley FX, Bagley DH. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol. 1997;158:2074.CrossRefPubMedGoogle Scholar
  52. 52.
    See WA. Continuous antegrade infusion of adriamycin as adjuvant therapy for upper tract urothelial malignancies. Urology. 2000;56:216.CrossRefPubMedGoogle Scholar
  53. 53.
    Burns JA, Williams RD, Hedican SP, O’Donnell MA: The treatment of upper tract transitional cell carcinoma with BCG plus interferon-alpha. In: American urological association annual meeting, 2001.Google Scholar
  54. 54.
    Katz MH, Lee MW, Gupta M. Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-alpha2B. J Endourol. 2007;21:374.CrossRefPubMedGoogle Scholar
  55. 55.
    Eshghi M. Upper Tract Urothelial Carcinoma. Presentation of NY-AUA Meeting 2007.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Joel Hillelsohn
    • 1
  • Ariel Schulman
    • 1
    • 2
  • Majid Eshghi
    • 1
  1. 1.Department of UrologyWestchester Medical Health Network/New York Medical CollegeValhallaUSA
  2. 2.Division of UrologyDuke University School of MedicineDurhamUSA

Personalised recommendations